The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

According to a study funded by Eli Lilly, the trial revealed that participants taking tirzepatide, the drug sold as ...

Drug maker Eli Lilly says data from a late-stage ... A new ABC News Investigation looks at weight loss drugs like Wegovy and Zepbound and how the high demand has contributed to ...